Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate | Zendy

Elise S. Eerenberg | Zendy; Pieter W. Kamphuisen | Zendy; Meertien K. Sijpkens | Zendy; Joost C.M. Meijers | Zendy; Harry R. Büller | Zendy; Marcel Levi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

Author(s) -

Elise S. Eerenberg,

Pieter W. Kamphuisen,

Meertien K. Sijpkens,

Joost C.M. Meijers,

Harry R. Büller,

Marcel Levi

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.029017

Subject(s) - rivaroxaban , dabigatran , medicine , anesthesia , partial thromboplastin time , anticoagulant , prothrombin time , idarucizumab , hemostasis , saline , thromboplastin , antidote , warfarin , coagulation , atrial fibrillation , toxicity

Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research